GlassScriptPhysician profile
Heather M Jones
NPI 1518958396
$6,718.08
in general payments reported to CMS, 2019-2025
38 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $514 · 2021: $786 · 2022: $780 · 2023: $1,017 · 2024: $1,200 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,444.27 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,318.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $584.51 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $578.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $524.51 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $345.97 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $321.48 | 2019-2025 | |
| Allergan, INC. | $175.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $138.87 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.24 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.71 | 2019-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $88.84 | 2021-2024 | Eliquis |
| Exact Sciences Corporation | $86.59 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $84.52 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $80.81 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.95 | 2022-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $62.40 | 2019-2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $54.31 | 2019-2023 | Austedo |
| Amarin Pharma, INC. | $51.48 | 2020-2021 | |
| Averitas Pharma INC. | $46.07 | 2023-2025 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $41.39 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $40.61 | 2025 | Rexulti |
| Pharmacosmos Therapeutics INC. | $34.17 | 2023 | Monoferric |
| Eisai INC. | $34.04 | 2021 | |
| Mylan Specialty L.P. | $31.30 | 2024 | Yupelri |
| Sanofi Pasteur INC. | $29.25 | 2021-2022 | |
| Abbott Laboratories | $28.63 | 2023-2024 | Octrode, Proclaim |
| Daiichi Sankyo INC. | $27.61 | 2024 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.59 | 2022 | |
| Horizon Therapeutics Plc | $18.03 | 2021 | |
| Nevro Corp. | $18.00 | 2022 | |
| Alkermes, INC. | $17.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.92 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.74 | 2019 | |
| Medtronic, INC. | $13.80 | 2022 | |
| Genentech USA, INC. | $12.57 | 2020 | |
| Kaleo, INC. | $11.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.